<codeBook xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xsi:schemaLocation="ddi:codebook:2_6 http://www.ddialliance.org/Specification/DDI-Codebook/2.6/XMLSchema/codebook.xsd" xmlns="ddi:codebook:2_6">
  <docDscr>
    <citation>
      <titlStmt>
        <titl xml:lang="sv">Data for: Cellular origin and characterization of autoantibodies against type I IFNs in COVID-19 and APS-1</titl>
        <parTitl xml:lang="en">Data for: Cellular origin and characterization of autoantibodies against type I IFNs in COVID-19 and APS-1</parTitl>
        <IDNo agency="SND">2026-253-1</IDNo>
        <IDNo agency="DOI">https://doi.org/10.48723/hqay-t924</IDNo>
      </titlStmt>
      <prodStmt>
        <producer xml:lang="en" abbr="SND">Swedish National Data Service</producer>
        <producer xml:lang="sv" abbr="SND">Svensk nationell datatjänst</producer>
      </prodStmt>
      <holdings URI="https://doi.org/10.48723/hqay-t924">Landing page</holdings>
    </citation>
  </docDscr>
  <stdyDscr>
    <citation>
      <titlStmt>
        <titl xml:lang="sv">Data for: Cellular origin and characterization of autoantibodies against type I IFNs in COVID-19 and APS-1</titl>
        <parTitl xml:lang="en">Data for: Cellular origin and characterization of autoantibodies against type I IFNs in COVID-19 and APS-1</parTitl>
        <IDNo agency="SND">2026-253-1</IDNo>
        <IDNo agency="DOI">https://doi.org/10.48723/hqay-t924</IDNo>
      </titlStmt>
      <rspStmt>
        <AuthEnty xml:lang="en" affiliation="Department of Medical Biochemistry and Biophysics [C2], Karolinska Institutet">Sun, Rui</AuthEnty>
        <AuthEnty xml:lang="sv" affiliation="Institutionen för medicinsk biokemi och biofysik, Karolinska Institutet">Sun, Rui</AuthEnty>
        <AuthEnty xml:lang="en" affiliation="Department of Medical Biochemistry and Biophysics [C2], Karolinska Institutet">Pan-Hammarström, Qiang</AuthEnty>
        <AuthEnty xml:lang="sv" affiliation="Institutionen för medicinsk biokemi och biofysik, Karolinska Institutet">Pan-Hammarström, Qiang</AuthEnty>
      </rspStmt>
      <prodStmt>
        <grantNo xml:lang="en" agency="Knut and Alice Wallenberg Foundation">KAW2020.0102</grantNo>
        <grantNo xml:lang="sv" agency="Knut and Alice Wallenberg Foundation">KAW2020.0102</grantNo>
        <grantNo xml:lang="en" agency="Swedish Research Council">2019-01302</grantNo>
        <grantNo xml:lang="sv" agency="Swedish Research Council">2020-06116</grantNo>
        <grantNo xml:lang="en" agency="EU Horizon 2020 Research and Innovation Program">ATAC, 101003650</grantNo>
      </prodStmt>
      <distStmt>
        <distrbtr xml:lang="en" abbr="SND" URI="https://snd.se">Swedish National Data Service</distrbtr>
        <distrbtr xml:lang="sv" abbr="SND" URI="https://snd.se">Svensk nationell datatjänst</distrbtr>
        <distDate xml:lang="en" date="2026-09-28" />
      </distStmt>
      <verStmt>
        <version elementVersion="1" elementVersionDate="2026-09-28" />
      </verStmt>
      <holdings URI="https://doi.org/10.48723/hqay-t924">Landing page</holdings>
    </citation>
    <stdyInfo>
      <subject>
        <keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D001327">Autoimmune Diseases</keyword>
        <keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D001327">Autoimmuna sjukdomar</keyword>
        <keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D001402">B-Lymphocytes</keyword>
        <keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D001402">B-lymfocyter</keyword>
        <keyword xml:lang="en" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D000086382">COVID-19</keyword>
        <keyword xml:lang="sv" vocab="MeSH" vocabURI="http://id.nlm.nih.gov/mesh/D000086382">Covid-19</keyword>
        <keyword xml:lang="en" vocab="SNOMEDCT" vocabURI="http://snomed.info/id/30621004">Abs - Autoantibodies</keyword>
        <keyword xml:lang="sv" vocab="SNOMEDCT" vocabURI="http://snomed.info/id/30621004">autoantikropp</keyword>
        <topcClas xml:lang="en" vocab="CESSDA Topic Classification" vocabURI="https://vocabularies.cessda.eu/vocabulary/TopicClassification?code=ScienceAndTechnology.Biotechnology">Biotechnology</topcClas>
        <topcClas xml:lang="sv" vocab="CESSDA Topic Classification" vocabURI="https://vocabularies.cessda.eu/vocabulary/TopicClassification?code=ScienceAndTechnology.Biotechnology">Bioteknik</topcClas>
      </subject>
      <abstract xml:lang="en" contentType="abstract">Autoantibodies (autoAbs) against type I interferons (IFNs) can severely compromise antiviral defense in a broad range of severe viral infections. To investigate the mechanisms underlying autoantibody development, we performed paired scRNA-seq and scBCR-seq on sorted IFN-α2-positive and IFN-α2-negative B cells, together with scRNA-seq of other non-B immune cells. PBMCs were obtained from eight aIFN⁺ patients with severe COVID-19, five aIFN⁻ patients with severe COVID-19, five patients with APS-1, and ten healthy donors.

The dataset is comprised of about 150 files and a total size of 810 GB.</abstract>
      <abstract xml:lang="sv" contentType="abstract">Autoantikroppar (autoAbs) mot typ I-interferoner (IFN) kan kraftigt försämra det antivirala immunförsvaret vid ett brett spektrum av svåra virusinfektioner. För att undersöka de mekanismer som ligger bakom utvecklingen av dessa autoantikroppar utförde vi kombinerad scRNA-sekvensering (scRNA-seq) och scBCR-sekvensering (scBCR-seq) på sorterade IFN-α2-positiva och IFN-α2-negativa B-celler, tillsammans med scRNA-seq av andra icke-B-immunceller. PBMC:er isolerades från åtta aIFN⁺-patienter med svår covid-19, fem aIFN⁻-patienter med svår covid-19, fem patienter med APS-1 och tio friska donatorer.

Det deponerade datasetet omfattar ungefär 150 filer och en total storlek på 810 GB.</abstract>
      <sumDscr>
        <nation xml:lang="en" abbr="SE">Sweden</nation>
        <nation xml:lang="sv" abbr="SE">Sverige</nation>
        <nation xml:lang="en" abbr="IT">Italy</nation>
        <nation xml:lang="sv" abbr="IT">Italien</nation>
        <universe xml:lang="en">Populations of the study includes eight patients with aIFN+ severe COVID-19. five aIFN- severe COVID-19 patients, five APS-1 patients, and ten healthy donors controls. The results of the analysis will refer to this specific group of individuals.</universe>
        <universe xml:lang="sv">Studiepopulationen består av åtta patienter med aIFN⁺ svår covid-19, fem patienter med aIFN⁻ svår covid-19, fem patienter med APS-1 samt tio friska kontroller. Resultaten från analyserna gäller denna specifika studiepopulation.</universe>
        <dataKind xml:lang="en">Numeric</dataKind>
        <dataKind xml:lang="en">Text</dataKind>
      </sumDscr>
    </stdyInfo>
    <method>
      <dataColl>
        <timeMeth xml:lang="en">Cross-section<concept vocab="DDI Time Method" vocabURI="https://vocabularies.cessda.eu/v2/vocabularies/TimeMethod/1.2.3?languageVersion=en-1.2.3">Cross-section</concept></timeMeth>
        <timeMeth xml:lang="sv">Tvärsnitt<concept vocab="DDI Time Method" vocabURI="https://vocabularies.cessda.eu/v2/vocabularies/TimeMethod/1.2.3?languageVersion=sv-1.2.3">Tvärsnitt</concept></timeMeth>
        <sampProc xml:lang="en">The samples used for the deposited scRNA-seq dataset were collected in Sweden and Italy under the relevant ethical approvals Dnr 2020-01558, Pavia Ethics Committee approval P-20200029440, and Dnr 2023-02698-02. The Italian samples were collected within the ATAC consortium at Fondazione IRCCS Policlinico San Matteo (Pavia, Italy) and transferred to Karolinska Institutet under a Material Transfer Agreement between Fondazione IRCCS Policlinico San Matteo and Karolinska Institutet. The approved Italian protocol includes Karolinska Institutet as a collaborating partner and permits anonymized samples to be analyzed by consortium partners. scRNA-seq data were generated at Karolinska Institutet from samples originating from both Sweden and Italy. The deposited dataset contains no direct personal identifiers.<concept vocab="DDI Sampling Procedure" vocabURI="https://vocabularies.cessda.eu/v2/vocabularies/SamplingProcedure/2.0.1?languageVersion=en-2.0.1">The samples used for the deposited scRNA-seq dataset were collected in Sweden and Italy under the relevant ethical approvals Dnr 2020-01558, Pavia Ethics Committee approval P-20200029440, and Dnr 2023-02698-02. The Italian samples were collected within the ATAC consortium at Fondazione IRCCS Policlinico San Matteo (Pavia, Italy) and transferred to Karolinska Institutet under a Material Transfer Agreement between Fondazione IRCCS Policlinico San Matteo and Karolinska Institutet. The approved Italian protocol includes Karolinska Institutet as a collaborating partner and permits anonymized samples to be analyzed by consortium partners. scRNA-seq data were generated at Karolinska Institutet from samples originating from both Sweden and Italy. The deposited dataset contains no direct personal identifiers.</concept></sampProc>
        <sampProc xml:lang="sv">De prover som användes för den deponerade scRNA-seq-datamängden samlades in i Sverige och Italien i enlighet med relevanta etiska godkännanden: Dnr 2020-01558, Pavia Ethics Committee approval P-20200029440 och Dnr 2023-02698-02. De italienska proverna samlades in inom ATAC-konsortiet vid Fondazione IRCCS Policlinico San Matteo (Pavia, Italien) och överfördes till Karolinska Institutet enligt ett Material Transfer Agreement mellan Fondazione IRCCS Policlinico San Matteo och Karolinska Institutet. Det godkända italienska protokollet inkluderar Karolinska Institutet som samarbetspartner och tillåter att anonymiserade prover analyseras av konsortiets samarbetspartner. scRNA-seq-data genererades vid Karolinska Institutet från prover med ursprung i både Sverige och Italien. Den deponerade datamängden innehåller inga direkta personidentifierande uppgifter.<concept vocab="DDI Sampling Procedure" vocabURI="https://vocabularies.cessda.eu/v2/vocabularies/SamplingProcedure/2.0.1?languageVersion=sv-2.0.1">De prover som användes för den deponerade scRNA-seq-datamängden samlades in i Sverige och Italien i enlighet med relevanta etiska godkännanden: Dnr 2020-01558, Pavia Ethics Committee approval P-20200029440 och Dnr 2023-02698-02. De italienska proverna samlades in inom ATAC-konsortiet vid Fondazione IRCCS Policlinico San Matteo (Pavia, Italien) och överfördes till Karolinska Institutet enligt ett Material Transfer Agreement mellan Fondazione IRCCS Policlinico San Matteo och Karolinska Institutet. Det godkända italienska protokollet inkluderar Karolinska Institutet som samarbetspartner och tillåter att anonymiserade prover analyseras av konsortiets samarbetspartner. scRNA-seq-data genererades vid Karolinska Institutet från prover med ursprung i både Sverige och Italien. Den deponerade datamängden innehåller inga direkta personidentifierande uppgifter.</concept></sampProc>
      </dataColl>
    </method>
    <dataAccs>
      <useStmt>
        <restrctn xml:lang="en">Access to data through SND. Access to data is restricted.</restrctn>
        <restrctn xml:lang="sv">Åtkomst till data via SND. Tillgång till data är begränsad.</restrctn>
        <conditions elementVersion="info:eu-repo-Access-Terms vocabulary">restrictedAccess</conditions>
      </useStmt>
    </dataAccs>
    <othrStdyMat />
  </stdyDscr>
</codeBook>